Definium Therapeutics appoints Roger Adsett to board, expanding to 7 directors

Definium Therapeutics, Inc.

Board increased from 6 to 7 directors; Adsett appointed effective Jan 29, 2026.
Adsett receives $40,000 annual cash retainer paid quarterly in arrears.
Granted option for 50,000 common shares; vests 1/3 on first anniversary, then monthly.
Not assigned to any board committees initially.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.